Precise Bio Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.79 Cr
as on 16-11-2024
- Paid Up Capital ₹ 1.79 Cr
as on 16-11-2024
- Company Age 19 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 49.10 Cr
as on 16-11-2024
- Satisfied Charges ₹ 4.75 Cr
as on 16-11-2024
- Revenue -22.02%
(FY 2023)
- Profit -29.37%
(FY 2023)
- Ebitda -25.86%
(FY 2023)
- Net Worth 6.32%
(FY 2023)
- Total Assets 22.70%
(FY 2023)
About Precise Bio Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.79 Cr and a paid-up capital of Rs 1.79 Cr.
The company currently has active open charges totaling ₹49.10 Cr. The company has closed loans amounting to ₹4.75 Cr, as per Ministry of Corporate Affairs (MCA) records.
Mehul Shah and Sunil Sukhathankar serve as directors at the Company.
- CIN/LLPIN
U24230MH2005PTC152453
- Company No.
152453
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Apr 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Precise Bio Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mehul Shah  | Director | 06-Apr-2005 | Current |
| Sunil Sukhathankar | Director | 20-Aug-2021 | Current |
Financial Performance of Precise Bio Pharma.
Precise Bio Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 22.02% decrease. The company also saw a substantial fall in profitability, with a 29.37% decrease in profit. The company's net worth moved up by a moderate rise of 6.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Precise Bio Pharma?
In 2023, Precise Bio Pharma had a promoter holding of 99.56% and a public holding of 0.44%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 29 Feb 2024 | ₹2.00 M | Open |
Others Creation Date: 05 Oct 2023 | ₹9.00 Cr | Open |
Axis Bank Limited Creation Date: 31 Mar 2022 | ₹5.00 Cr | Open |
How Many Employees Work at Precise Bio Pharma?
Precise Bio Pharma has a workforce of 221 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Precise Bio Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Precise Bio Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
